Printer Friendly

ROBERTS PHARMACEUTICAL ANNOUNCES ACQUISITION OF CURRENTLY MARKETED ANTI-PARKINSON DRUG FROM NORWICH EATON PHARMACEUTICALS

   ROBERTS PHARMACEUTICAL ANNOUNCES ACQUISITION OF CURRENTLY MARKETED
         ANTI-PARKINSON DRUG FROM NORWICH EATON PHARMACEUTICALS
    EATONTOWN, N.J., Dec. 10 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has purchased exclusive rights to Dopar(R), an anti-Parkinson prescription pharmaceutical product currently sold by Norwich Eaton Pharmaceuticals, Inc. of Norwich, N.Y.
    Norwich Eaton is a wholly owned subsidiary of The Procter & Gamble Company (NYSE: PG).  Roberts will immediately begin active marketing for Dopar through its own sales and marketing organization.  Financial terms were not disclosed.
    Dopar is prescribed predominantly by specialists for the symptomatic treatment of Parkinson's Disease.  Roberts chairman and CEO, Dr. Robert Vukovich, commented on the purchase, "The acquisition of Dopar forms the basis for the early establishment of a relationship between Roberts and neurologic specialists.  This relationship will be of significant advantage to our company when we receive FDA approval for Amatine, another product to be promoted to neurologists."
    Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad.  The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions.  Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
    -0-        12/10/91
    /CONTACT:  Anthony P. Maris of Roberts Pharmaceutical, 908-389-1182/
    (RPCX PG) CO:  Roberts Pharmaceutical Corporation ST:  New Jersey IN:  MTC SU:  TNM FC-TS -- NY019 -- 0929 12/10/91 10:25 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 1991
Words:245
Previous Article:BOOKER PLC TO SELL P. LEINER SHARES
Next Article:THERMO PROCESS SYSTEMS INC. BEGINS CONSTRUCTION OF THIRD SOIL-RECYCLING CENTER
Topics:


Related Articles
ROBERTS PHARMACEUTICALS ANNOUNCES ACQUISITION OF THREE MARKETED U.K. AND IRISH BRANDS FROM BOEHRINGER INGELHEIM
YAMANOUCHI TO PURCHASE EQUITY POSITION IN ROBERTS PHARMACEUTICALS
ROBERTS PHARMACEUTICALS COMPLETES ACQUISITION OF HAUCK PHARMACEUTICALS
PROCTER & GAMBLE TO ACQUIRE ROEHM PHARMA
ROBERTS PHARMACEUTICALS TO ACQUIRE MARKETED RESPIRATORY DRUG FROM SMITHKLINE BEECHAM
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF SMITHKLINE BEECHAM RESPIRATORY DRUG
ROBERTS PHARMACEUTICAL ACQUIRES COMHIST ANTI-ALLERGY PRESCRIPTION PHARMACEUTICAL PRODUCT LINE FROM PROCTER & GAMBLE PHARMACEUTICALS
ROBERTS PHARMACEUTICAL ACQUIRES THREE CURRENTLY MARKETED PRODUCT LINES FROM G.D. SEARLE
ROBERTS PHARMACEUTICAL ACQUIRES THREE CURRENTLY MARKETED PRODUCT LINES FROM G.D. SEARLE
ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES FOUR PRESCRIPTION PRODUCTS FROM SEARLE CANADA INC.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters